147 related articles for article (PubMed ID: 15545579)
1. Auditory effects after organ preservation protocol for laryngeal/hypopharyngeal carcinomas.
Liberman PH; Schultz C; Gomez MV; Carvalho AL; Pellizzon AC; Testa JR; Feher O; Kowalski LP
Arch Otolaryngol Head Neck Surg; 2004 Nov; 130(11):1265-8. PubMed ID: 15545579
[TBL] [Abstract][Full Text] [Related]
2. Voice and swallowing in patients enrolled in a larynx preservation trial.
Carrara-de Angelis E; Feher O; Barros AP; Nishimoto IN; Kowalski LP
Arch Otolaryngol Head Neck Surg; 2003 Jul; 129(7):733-8. PubMed ID: 12874074
[TBL] [Abstract][Full Text] [Related]
3. Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas.
Nishimura G; Tsukuda M; Horiuchi C; Satake K; Yoshida T; Nagao J; Kawakami M; Kondo N; Arai Y; Taguchi T; Matsuda H; Mikami Y
Auris Nasus Larynx; 2007 Dec; 34(4):499-504. PubMed ID: 17604583
[TBL] [Abstract][Full Text] [Related]
4. Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial.
Cmelak AJ; Murphy BA; Burkey B; Douglas S; Shyr Y; Netterville J
Head Neck; 2007 Apr; 29(4):315-24. PubMed ID: 17252600
[TBL] [Abstract][Full Text] [Related]
5. Hyperfractionated radiotherapy and concomitant cisplatin for locally advanced laryngeal and hypopharyngeal carcinomas: final results of a single institutional program.
de la Vega FA; García RV; Domínguez D; Iturre EV; López EM; Alonso SM; Romero P; Sola JM
Am J Clin Oncol; 2003 Dec; 26(6):550-7. PubMed ID: 14663370
[TBL] [Abstract][Full Text] [Related]
6. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
7. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of a prospective multicenter phase II study to preserve the larynx function using concomitant boost radiochemotherapy with Carboplatin.
Rudat V; Eckel H; Volling P; Schröder M; Staar S; Wallner F; Wannenmacher M; Dietz A
Radiother Oncol; 2008 Oct; 89(1):33-7. PubMed ID: 18621428
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
10. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.
Haynes DS; O'Malley M; Cohen S; Watford K; Labadie RF
Laryngoscope; 2007 Jan; 117(1):3-15. PubMed ID: 17202923
[TBL] [Abstract][Full Text] [Related]
11. Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
Tai SK; Yang MH; Wang LW; Tsai TL; Chu PY; Wang YF; Huang JL; Chang SY
Jpn J Clin Oncol; 2008 Aug; 38(8):521-7. PubMed ID: 18697758
[TBL] [Abstract][Full Text] [Related]
12. Larynx preservation with primary non-surgical treatment for loco-regionally advanced larynx cancer.
Corry J; Rischin D; Cotton S; D'Costa I; Chua M; Vallance N; Lyons B; Kleid S; Sizeland A; Peters LJ
J Med Imaging Radiat Oncol; 2011 Apr; 55(2):229-35. PubMed ID: 21501415
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers.
Lee NY; O'Meara W; Chan K; Della-Bianca C; Mechalakos JG; Zhung J; Wolden SL; Narayana A; Kraus D; Shah JP; Pfister DG
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):459-68. PubMed ID: 17493769
[TBL] [Abstract][Full Text] [Related]
14. Decreased hearing after combined modality therapy for head and neck cancer.
Pearson SE; Meyer AC; Adams GL; Ondrey FG
Am J Otolaryngol; 2006; 27(2):76-80. PubMed ID: 16500467
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx, or hypopharynx.
Ozer E; Grecula JC; Agrawal A; Rhoades CA; Young DC; Schuller DE
Laryngoscope; 2006 Apr; 116(4):607-12. PubMed ID: 16585867
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy-induced hearing loss in patients with laryngeal and hypopharyngeal carcinomas.
Gudelj G; Trotić R; Herceg T; Parazajder D; Vagić D; Geber G
Coll Antropol; 2014 Sep; 38(3):945-8. PubMed ID: 25420378
[TBL] [Abstract][Full Text] [Related]
17. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
Chan SH; Ng WT; Kam KL; Lee MC; Choi CW; Yau TK; Lee AW; Chow SK
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1335-42. PubMed ID: 18922648
[TBL] [Abstract][Full Text] [Related]
18. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study.
Low WK; Toh ST; Wee J; Fook-Chong SM; Wang DY
J Clin Oncol; 2006 Apr; 24(12):1904-9. PubMed ID: 16622266
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial).
Dietz A; Rudat V; Dreyhaupt J; Pritsch M; Hoppe F; Hagen R; Pfreundner L; Schröder U; Eckel H; Hess M; Schröder M; Schneider P; Jens B; Zenner HP; Werner JA; Engenhardt-Cabillic R; Vanselow B; Plinkert P; Niewald M; Kuhnt T; Budach W; Flentje M
Eur Arch Otorhinolaryngol; 2009 Aug; 266(8):1291-300. PubMed ID: 18972123
[TBL] [Abstract][Full Text] [Related]
20. Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma.
Majem M; Mesia R; Mañós M; Gomez J; Galiana R; Cardenal F; Juan A; Montes A; Perez FJ; Nogues J; Llluch JR
Laryngoscope; 2006 Sep; 116(9):1651-6. PubMed ID: 16954998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
